Circulating cell-free DNA as a prognostic and predictive biomarker in non-small cell lung cancer.

摘要: // Bo Ai 1 , Huiquan Liu 2 Yu Huang Ping Peng Department of Thoracic Surgery, Tongji Hospital, Medical College, Huazhong University Science and Technology, Hubei, Wuhan 430030, People’s Republic China Oncology, Correspondence to: Peng, email: pengpingtjh@163.com Keywords: circulating cell-free DNA, non-small cell lung cancer, prognosis, biomarker, meta-analysis Received: February 28, 2016      Accepted: May 29, Published: June 15, 2016 ABSTRACT Circulating DNA (cfDNA), which can be obtained from plasma or serum by non-invasive procedures, has showed great potential to predict treatment response survival for cancer patients. Several studies have assessed the prognostic predictive value cfDNA in (NSCLC). However, these were often small reported varying results. To address this issue, a was carried out. A total 22 involving 2518 patients subjected final analysis. Our results indicated that NSCLC with higher concentration had shorter median progression-free (PFS) overall (OS) time. In addition, high levels significantly associated poor PFS (hazard ratio HR, 1.32; 95% CI, 1.02-1.71) OS (HR, 1.64; 1.26-2.15). With respect tumor specific mutations, we failed reveal significant differences 1.30; 0.66-2.56) 1.05; 0.49-2.25) when grouped according KRAS genotype detected cfDNA. harbored EGFR activating mutation greater chance EGFR-TKIs (odds OR, 1.96; 1.59-2.42). No publication bias study. conclusion, could act as biomarker NSCLC.